Article
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
PLoS genetics - 1 Feb 2014
Borad Mitesh J, Champion Mia D, Egan Jan B, Liang Winnie S, Fonseca Rafael, Bryce Alan H, McCullough Ann E, Barrett Michael T, Hunt Katherine, Patel Maitray D, Young Scott W, Collins Joseph M, Silva Alvin C, Condjella Rachel M, Block Matthew, McWilliams Robert R, Lazaridis Konstantinos N, Klee Eric W, Bible Keith C, Harris Pamela, Oliver Gavin R, Bhavsar Jaysheel D, Nair Asha A, Middha Sumit, Asmann Yan, Kocher Jean-Pierre, Schahl Kimberly, Kipp Benjamin R, Barr Fritcher Emily G, Baker Angela, Aldrich Jessica, Kurdoglu Ahmet, Izatt Tyler, Christoforides Alexis, Cherni Irene, Nasser Sara, Reiman Rebecca, Phillips Lori, McDonald Jackie, Adkins Jonathan, Mastrian Stephen D, Placek Pamela, Watanabe Aprill T, Lobello Janine, Han Haiyong, Von Hoff Daniel, Craig David W, Stewart A Keith, Carpten John D
Abstract excerpt
Advanced cholangiocarcinoma continues to harbor a difficult prognosis and therapeutic options have been limited. During the course of a clinical trial of whole genomic sequencing seeking druggable targets, we examined six patients with advanced cholangiocarcinoma. Integrated genome-wide and whole transcriptome sequence analyses were performed on tumors from six patients with advanced, sporadic intrahepatic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.